导航牙科并发症二次到抗瘤剂-一个全面的审查
Ion Alexandru Popovici1, Lidia Anca Kajanto2, Laura Roxana Popovici2
1Department of Implant Prosthetic Therapy, Faculty of Dentistry, University of Medicine and Pharmacy "Carol Davila" Bucharest, 010221 Bucharest, Romania.
新型癌症疗法,包括向性药物,可以引起显著的口腔副作用,如炎和骨缩. 预防性牙科护理和跨学科的合作对于管理这些并发症至关重要.
科学领域:
- 在瘤学瘤学.
- 口腔医学是指口腔医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统和新型抗癌疗法携带口腔并发症的风险.
- 向药物虽然比化疗毒性低,但仍然会导致显著的口服不良事件.
- 与药物相关的下巴骨硬化 (MRONJ) 是一个关键问题,特别是在骨修饰剂方面.
研究的目的:
- 系统地审查与传统和新型抗癌疗法相关的口腔并发症.
- 为了界定这些口腔毒性的致病性.
- 强调预防策略和跨学科的护理.
主要方法:
- 对抗癌症疗法的口服并发症的文献进行系统审查.
- 分析与向药物,化疗和骨修饰剂相关的不良事件.
- 检查口腔毒性的多因素病原性.
主要成果:
- 向性药物和免疫检查点抑制剂与粘膜炎,唾液功能障碍,失血症和MRONJ有关.
- 骨修饰剂 (双酸盐,苏马布) 显著增加了MRONJ的风险.
- 发病包括直接的细胞毒性,受损的愈合和二次感染.
结论:
- 在治疗前进行牙科评估和预防策略至关重要.
- 像激光疗法和血小板缩剂这样的辅助疗法可以减轻副作用.
- 瘤学家和牙医之间的跨学科合作改善了患者的治疗结果和生活质量.
更多相关视频
05:54Real-Time Dynamic Navigation System for the Precise Quad-Zygomatic Implant Placement in a Patient with a Severely Atrophic Maxilla
Published on: October 18, 2021
07:38Radiation Treatment of Organotypic Cultures from Submandibular and Parotid Salivary Glands Models Key In Vivo Characteristics
Published on: May 17, 2019
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Tonsillitis II: Management
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Tracheostomy Decannulation
Description of the Procedure
Decannulation refers to the permanent removal of the tracheostomy tube, signaling the resolution of the condition that initially necessitated the tracheostomy. The process requires a well-coordinated interplay between...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
